For research use only. Not for therapeutic Use.
Bevenopran is a peripheral μ-opioid receptor antagonist[1][2].
Bevenopran is a peripheral μ-opioid receptor antagonist. Bevenopran is currently under investigation for the treatment of opioid-induced bowel dysfunction (OBD)[1]. Bevenopran tends to increase bowel movement (BM) frequency, especially for 0.1 mg twice daily and 4 mg daily, respectively[1].
| Catalog Number | I004173 |
| CAS Number | 676500-67-7 |
| Synonyms | 5-[2-methoxy-4-[[2-(oxan-4-yl)ethylamino]methyl]phenoxy]pyrazine-2-carboxamide |
| Molecular Formula | C20H26N4O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C20H26N4O4/c1-26-18-10-15(11-22-7-4-14-5-8-27-9-6-14)2-3-17(18)28-19-13-23-16(12-24-19)20(21)25/h2-3,10,12-14,22H,4-9,11H2,1H3,(H2,21,25) |
| InChIKey | ZGCYVRNZWGUXNQ-UHFFFAOYSA-N |
| SMILES | COC1=C(C=CC(=C1)CNCCC2CCOCC2)OC3=NC=C(N=C3)C(=O)N |
| Reference | [1]. Diego L, et al. Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opin Investig Drugs. 2011 Aug;20(8):1047-56. [2]. Siemens W, et al. Advances in pharmacotherapy for opioid-induced constipation – a systematic review. Expert Opin Pharmacother. 2015 Mar;16(4):515-32. |
